OC
CLVS

Oppenheimer & Co’s Clovis Oncology, Inc. CLVS Stock Holding History

Oppenheimer & Co’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,717
Closed -$62K – 1424
2020
Q3 		$62K Sell
10,717
-3,583
-25% -$21.4K ﹤0.01% 1252
2020
Q2 		$97K Sell
14,300
-9,535
-40% -$72.2K ﹤0.01% 1207
2020
Q1 		$152K Sell
23,835
-20
-0.1% -$160 ﹤0.01% 1073
2019
Q4 		$249K Sell
23,855
-685
-3% -$4.98K 0.01% 1095
2019
Q3 		$96K Sell
24,540
-5,415
-18% -$43.8K ﹤0.01% 1216
2019
Q2 		$445K Buy
29,955
+1,782
+6% +$32.2K 0.01% 860
2019
Q1 		$699K Buy
28,173
+11,521
+69% +$289K 0.02% 697
2018
Q4 		$299K Buy
+16,652
New +$340K 0.01% 942
2015
Q4 		– Sell
-3,001
Closed -$276K – 1392
2015
Q3 		$276K Sell
3,001
-1,098
-27% -$95K 0.01% 1022
2015
Q2 		$360K Buy
4,099
+1,098
+37% +$94K 0.01% 1023
2015
Q1 		$223K Buy
+3,001
New +$212K 0.01% 1245

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oppenheimer & Co's CLVS Position: Q4 2020 in Review

Oppenheimer & Co sold out of Clovis Oncology, Inc. (CLVS) in Q4 2020, closing a stake of 10,717 shares — an estimated $62K sold.

Oppenheimer & Co first reported a position in CLVS in Q1 2015 and held it in 11 quarters. The position peaked at $699K in Q1 2019. 159 funds tracked by Wall St. Rank hold CLVS as of Q4 2020.

  • Oppenheimer & Co reported no remaining Clovis Oncology, Inc. position as of Q4 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 10,717 Clovis Oncology, Inc. shares in Q4 2020, an estimated $62K.
  • Oppenheimer & Co first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 11 quarters.
  • Oppenheimer & Co's Clovis Oncology, Inc. position peaked at $699K in Q1 2019.
  • 159 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2020.

Based on Oppenheimer & Co's 13F filing for Q4 2020, filed 11 Feb 2021.